CN110996979A - 颈肌张力障碍的治疗方法 - Google Patents

颈肌张力障碍的治疗方法 Download PDF

Info

Publication number
CN110996979A
CN110996979A CN201880042201.4A CN201880042201A CN110996979A CN 110996979 A CN110996979 A CN 110996979A CN 201880042201 A CN201880042201 A CN 201880042201A CN 110996979 A CN110996979 A CN 110996979A
Authority
CN
China
Prior art keywords
botulinum toxin
positively charged
gly
composition
duration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880042201.4A
Other languages
English (en)
Chinese (zh)
Inventor
C·L·鲁格
J·M·沃
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Revance Therapeuticals Inc
Original Assignee
Revance Therapeuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Revance Therapeuticals Inc filed Critical Revance Therapeuticals Inc
Publication of CN110996979A publication Critical patent/CN110996979A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
CN201880042201.4A 2017-05-18 2018-05-18 颈肌张力障碍的治疗方法 Pending CN110996979A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762508324P 2017-05-18 2017-05-18
US62/508,324 2017-05-18
PCT/US2018/033397 WO2018213710A1 (en) 2017-05-18 2018-05-18 Methods of treatment for cervical dystonia

Publications (1)

Publication Number Publication Date
CN110996979A true CN110996979A (zh) 2020-04-10

Family

ID=64274745

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880042201.4A Pending CN110996979A (zh) 2017-05-18 2018-05-18 颈肌张力障碍的治疗方法

Country Status (13)

Country Link
US (3) US20200179498A1 (enExample)
EP (1) EP3624819A4 (enExample)
JP (1) JP2020520917A (enExample)
KR (2) KR20250037595A (enExample)
CN (1) CN110996979A (enExample)
AU (2) AU2018270092B2 (enExample)
BR (1) BR112019024082A2 (enExample)
CA (1) CA3064070A1 (enExample)
CO (1) CO2019014212A2 (enExample)
MX (1) MX2019013716A (enExample)
PH (1) PH12019502578A1 (enExample)
RU (1) RU2019141383A (enExample)
WO (1) WO2018213710A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2490986T3 (pl) * 2009-10-21 2019-03-29 Revance Therapeutics, Inc. Sposoby i systemy oczyszczania nieskompleksowanej neurotoksyny botulinowej
US12161703B2 (en) 2017-08-28 2024-12-10 Revance Therapeutics, Inc. Transmucosal botulinum toxin compositions, kits, and methods for treating bladder disorders
EP4228599A4 (en) * 2020-10-13 2025-03-12 ReVance Therapeutics, Inc. METHODS FOR TREATMENT OF CERVICAL DYSTONIA
AU2022223782A1 (en) * 2021-02-21 2023-09-21 Revance Therapeutics, Inc. Methods of and compositions for treatment of upper limb spasticity
WO2025059665A1 (en) 2023-09-15 2025-03-20 Revance Therapeutics, Inc. Serial treatment with botulinum toxin for cervical dystonia

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100168023A1 (en) * 2008-12-31 2010-07-01 Revance Therapeutics, Inc. Injectable Botulinum Toxin Formulations
EP2656859A2 (en) * 2004-03-03 2013-10-30 ReVance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8557256B2 (en) * 1993-12-28 2013-10-15 Allergan, Inc. Treatment for cervical dystonia with the neurotoxic component of a botulinum toxin
TW574036B (en) * 1998-09-11 2004-02-01 Elan Pharm Inc Stable liquid compositions of botulinum toxin
BRPI1015938A2 (pt) * 2009-06-25 2016-09-27 Revance Therapeutics Inc formulações da toxina botulínica livre de albumina
US8147848B2 (en) * 2009-08-26 2012-04-03 Allergan, Inc. Method for treating premature ejaculation with a botulinum neurotoxin
HRP20171483T1 (hr) * 2011-01-07 2017-12-01 Revance Therapeutics, Inc. Topikalni pripravak koji se sastoji od botulinskog toksina i boje
AU2012283968B2 (en) * 2011-07-20 2016-04-14 Allergan, Inc. Botulinum toxins for use in a method for treatment of adipose deposits
CA3003447A1 (en) 2015-10-29 2017-05-04 Revance Therapeutics, Inc. Injectable botulinum toxin formulations and methods of use thereof having long duration of therapeutic or cosmetic effect
WO2019090257A1 (en) * 2017-11-03 2019-05-09 Revance Therapeutics, Inc. Botulinum toxin formulations and methods of use thereof in plantar fasciitis with extended duration of effect
MX2020005785A (es) * 2017-12-04 2020-10-28 Revance Therapeutics Inc Formulaciones inyectables de toxina botulínica y métodos de uso de las mismas que tienen una alta tasa de respuesta y una larga duración del efecto.
RU2741221C1 (ru) 2020-04-30 2021-01-22 Федеральное государственное автономное образовательное учреждение высшего образования "Крымский федеральный университет имени В.И. Вернадского" (ФГАОУ ВО "КФУ им. В.И. Вернадского") Способ комплексной реабилитации двигательной функции верхней конечности у больных детским церебральным параличом

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2656859A2 (en) * 2004-03-03 2013-10-30 ReVance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
US20100168023A1 (en) * 2008-12-31 2010-07-01 Revance Therapeutics, Inc. Injectable Botulinum Toxin Formulations
CN102300584A (zh) * 2008-12-31 2011-12-28 雷文斯治疗公司 可注射的肉毒杆菌毒素制剂

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JOSEPH JANKOVIC: "Treatment of Cervical Dystonia With Botulinum Toxin" *

Also Published As

Publication number Publication date
US20200179498A1 (en) 2020-06-11
JP2020520917A (ja) 2020-07-16
KR20200006587A (ko) 2020-01-20
RU2019141383A (ru) 2021-06-18
KR102777928B1 (ko) 2025-03-10
RU2019141383A3 (enExample) 2022-01-19
US20250319168A1 (en) 2025-10-16
CA3064070A1 (en) 2018-11-22
AU2018270092B2 (en) 2025-04-17
BR112019024082A2 (pt) 2020-06-16
NZ759612A (en) 2024-01-26
US12257293B2 (en) 2025-03-25
US20220096610A1 (en) 2022-03-31
CO2019014212A2 (es) 2020-01-17
PH12019502578A1 (en) 2020-07-20
MX2019013716A (es) 2020-10-12
EP3624819A1 (en) 2020-03-25
EP3624819A4 (en) 2021-03-24
AU2018270092A1 (en) 2019-12-19
WO2018213710A1 (en) 2018-11-22
AU2025205532A1 (en) 2025-08-07
KR20250037595A (ko) 2025-03-17

Similar Documents

Publication Publication Date Title
JP6559849B2 (ja) 注射用ボツリヌス毒素製剤
JP5690785B2 (ja) 改良されたボツリヌス毒素組成物
US12257293B2 (en) Methods of treatment for cervical dystonia
JP6043627B2 (ja) アルブミン非含有ボツリヌス毒素製剤
EP2413947B1 (en) Methods and compositions for treating skin conditions associated with vascular hyper-reactivity
US20240269246A1 (en) Methods for treating cervical dystonia
HK40020585A (en) Methods of treatment for cervical dystonia
WO2025059665A1 (en) Serial treatment with botulinum toxin for cervical dystonia
CN117693366A (zh) 用于治疗上肢痉挛的方法和组合物
HK1240854A1 (en) Injectable botulinum toxin formulations
HK1162925A (en) Injectable botulinum toxin formulations

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40020585

Country of ref document: HK